Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network

Cinnie Yentia Soekojo, Kihyun Kim, Shang Yi Huang, Chor Sang Chim, Naoki Takezako, Hideki Asaoku, Hideo Kimura, Hiroshi Kosugi, Junichi Sakamoto, Sathish Kumar Gopalakrishnan, Chandramouli Nagarajan, Yuan Wei, Rajesh Moorakonda, Shu Ling Lee, Je Jung Lee, Sung Soo Yoon, Jin Seok Kim, Chang Ki Min, Jae Hoon Lee, Brian DurieWee Joo Chng

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Pomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma. However, the data in Asian patients remain limited. We conducted a prospective phase two clinical trial in major cancer centers in Singapore, South Korea, Taiwan, Japan and Hong Kong to assess the efficacy and safety of pomalidomide and dexamethasone combination (PomDex) +/− cyclophosphamide in Asian patients with relapsed/refractory multiple myeloma who failed lenalidomide and bortezomib. Patients were treated with pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly). If there is less than a minimal response after three cycles of PomDex, cyclophosphamide 300 mg/m2 can be added (PomCyDex). A total of 136 patients were enrolled. The median PFS was 9 and 10.8 months for the PomDex and PomCyDex group, respectively. The median OS was 16.3 months. This regimen appears to be active across age groups and prior lines of treatment. This combination was overall well tolerated with grade 3 and 4 adverse events of mainly cytopenias. PomDex is highly active and well-tolerated in Asian patients. The addition of cyclophosphamide can improve the response and outcomes further in patients with suboptimal response to PomDex.

Original languageEnglish
Article number83
JournalBlood Cancer Journal
Volume9
Issue number10
DOIs
Publication statusPublished - 2019 Oct 1

Bibliographical note

Publisher Copyright:
© 2019, The Author(s).

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network'. Together they form a unique fingerprint.

Cite this